Does hydroxyapatite coating have no advantage over porous coating in primary total hip arthroplasty? A meta-analysis

Chen, Yun-Lin; Lin, Tiao; Liu, An; Shi, Ming-Min; Hu, Bin; Shi, Zhong-li; Yan, Shi-Gui

doi:10.1186/s13018-015-0161-4

Journal of Orthopaedic Surgery and Research

Table 3 Methodologic quality of included studies

From: Does hydroxyapatite coating have no advantage over porous coating in primary total hip arthroplasty? A meta-analysis

Study	Randomized adequately ^a	Allocation concealed	Similar baseline	Patient blinded	Care provider blinded	Outcome assessor blinded	Avoid selective reporting	Similar or avoided cofactors	Patients’ compliance ^b	Acceptable drop-out rate ^c	Similar timing	ITT analysis ^d	Quality ^e
Hamadouche et al. [34]	Yes	Unclear	Yes	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	No	High
Incavo et al. [32]	Yes	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	High
Kim et al. [23]	Yes	Yes	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	High
Kim et al. [24]	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	No	High
Lee and Lee [33]	Yes	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	High
Søballe et al. [4]	Yes	Yes	Yes	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	No	High
Tanzer et al. [22]	Yes	Yes	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	High
Tanzer et al. [31]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	High
Yee et al. [30]	Yes	Unclear	Yes	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	No	High
Yoon et al. [29]	Yes	Yes	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	High
Camazzola et al. [28]	Yes	Unclear	Yes	Unclear	Unclear	Yes	Yes	Yes	Yes	No	Yes	No	Moderate
Dorr et al. [16]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Unclear	Yes	Unclear	Moderate
Lombardi, Jr. et al. [12]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	No	Yes	No	Moderate
Mcpherson et al. [36]	Unclear	Unclear	Yes	Yes	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	Moderate
Parvizi et al. [9]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	Moderate
Paulsen et al. [38]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	Moderate
Ranawat et al. [35]	Yes	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	No	Yes	No	Moderate
Rothman et al. [10]	No	Unclear	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Moderate
Sanchez-Sotelo et al. [37]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yesc	Yes	Yes	Yes	No	Moderate
Sano et al. [39]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	Moderate
Santori et al. [14]	Unclear	Unclear	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	Yes	No	Moderate

^aOnly if the method of sequence generated was explicitly described could get a “Yes”; sequence generated by “Dates of Admission” or “Patients Number” received a “No”.
^bIntermittent treatment or therapy duration less than 6 months means “Yes”, otherwise “No”.
^cDrop-out rate ≥ 20% means “No”, otherwise “Yes”.
^d ITT intention-to-treat, only if all randomized patients are analyzed in the group they were allocated to could receive a “Yes”.
^eThe frequency of “Yes” as 7 or greater means “High”, greater than 4 but less means “Moderate”, 4 or less means “Low”.

Back to article page

ISSN: 1749-799X

Contact us

Submission enquiries: journalsubmissions@springernature.com